

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: James Martin Lenhard

Serial No.: To be assigned

Filed: Concurrently herewith

For: METHODS OF SCREENING PROTEASE INHIBITORS, OF INDUCING MICE
SUSCEPTIBLE TO HIV PROTEASE INHIBITOR-INDUCED DYSLIPIDEMIA,
AND GENES ASSOCIATED THEREWITH

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☐ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/US00/01205 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449. (37 CFR 1.98(d)), and applicants understand that copies have been supplied to the USPTO by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Date: 17 July 2001

Respectfully Submitted,

Elizabeth Selby
Elizabeth Selby
Attorney of Record, Reg. No. 38,298

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
(919) 483-3934

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

Date: 17 July 2001

Marilyn Eldridge
Marilyn Eldridge

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG3610USW		SERIAL NO. To be assigned 09/889471			
				APPLICANT James Martin Lenhard					
				FILING DATE Concurrently herewith				GROUP	
U.S. PATENT DOCUMENTS									
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate		
Continue on page _____									
FOREIGN PATENT DOCUMENTS									
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No		
Continue on page _____									
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
	CA	Carr, A. et al., <i>A Syndrome of Peripheral Lipodystrophy, Hyperlipidaemia and Insulin Resistance in Patients Receiving HIV Protease Inhibitors</i> , <u>AIDS</u> , 12(7):F51-F58 (1998)							
	CB	Carr, A. et al., <i>Pathogenesis of HIV-1-Protease Inhibitor-Associated Peripheral Lipodystrophy, Hyperlipidaemia, and Insulin Resistance</i> , <u>Lancet</u> , 351:1881-1883 (1998)							
	CC	Shaw, A.J. et al., <i>Disorders of Fat Distribution in HIV Infection</i> , <u>International Journal of STD & AIDS</u> , 9:595-599 (1998)							
	CD	Shimomura, I. et al., <i>Insulin Resistance and Diabetes Mellitus in Transgenic Mice Expressing Nuclear SREBP-1c in Adipose Tissue: Model for Congenital Generalized Lipodystrophy</i> , <u>Genes & Development</u> , 12:3182-3194 (1998)							
Continue on page _____									
EXAMINER						DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									